Acadia Pharma Presents Additional Data From Phase 2 RADIANT Trial Evaluating Remlifanserin For Treatment Of Hallucinations And Delusions Associated With ADP, At 2026 CTAD Conference
Benzinga Newsdesk 15 hours ago
News
− New analyses show a consistent efficacy signal with once-daily 60 mg remlifanserin across multiple measures of psychosis, with larger estimated treatment effects with increasing baseline psychosis severityAcadia
− New analyses show a consistent efficacy signal with once-daily 60 mg remlifanserin across multiple measures of psychosis, with larger estimated treatment effects with increasing baseline psychosis severity
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today presented additional data from the Phase 2 RADIANT trial evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) during an oral presentation at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston. Building on previously announced topline results, new analyses provided further evidence of a consistent efficacy signal with once-daily 60 mg remlifanserin across multiple measures of psychosis and new insights into treatment effect by baseline psychosis severity.
As previously reported, once-daily 60 mg remlifanserin narrowly missed the primary endpoint, with a −2.2-point improvement versus placebo on SAPS-H+D at Week 6 (p=0.0603), and achieved nominal significance on the key secondary endpoint, CGI-S-ADP (p=0.0077). The 30 mg dose showed minimal efficacy versus placebo, supporting a dose-response relationship.
